Parkinson's disease as an extrapyramidal pathology is accompanied by some non-motor symptoms (depression, cognitive disorders, and sleep disturbance), which are based on disturbances of nigrostriatal dopaminergic neurotransmission supplemented by disorganization of other neuromediator systems. Traditional antiparkinsonian drugs with different cellular mechanism of action are capable of restricting these symptoms in patients and on animal models, while exhibiting their own psychotropic activity. This circumstance should be taken into account in assessing the pharmacological activity profiles of drugs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease.
J Neurol
January 2025
Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Background: Impaired impulse control is often seen in Parkinson's disease (PD) patients using dopamine agonists.
Methods: We performed a therapeutic drug monitoring study of 100 PD patients using ropinirole or pramipexole extended release. Three blood samples were collected on the same day.
The effects of pramipexole on motivational vigour during a saccade task: a placebo-controlled study in healthy adults.
Psychopharmacology (Berl)
July 2024
Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Level 6 West Wing, Oxford, OX3 9DU, UK.
Motivation allows us to energise actions when we expect reward and is reduced in depression. This effect, termed motivational vigour, has been proposed to rely on central dopamine, with dopaminergic agents showing promise in the treatment of depression. This suggests that dopaminergic agents might act to reduce depression by increasing the effects of reward or by helping energise actions.
View Article and Find Full Text PDFL-DOPA and oxytocin influence the neural correlates of performance monitoring for self and others.
Psychopharmacology (Berl)
May 2024
Department of Clinical Psychology, Institute of Psychology, Leiden University, Leiden, The Netherlands.
Rationale: The ability to monitor the consequences of our actions for others is imperative for flexible and adaptive behavior, and allows us to act in a (pro)social manner. Yet, little is known about the neurochemical mechanisms underlying alterations in (pro)social performance monitoring.
Objective: The aim of this functional magnetic resonance imaging (fMRI) study was to improve our understanding of the role of dopamine and oxytocin and their potential overlap in the neural mechanisms underlying performance monitoring for own versus others' outcomes.
Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer's disease therapy.
Psychopharmacology (Berl)
May 2024
Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, 10962, USA.
Rationale: The β-secretase BACE1 initiates amyloid-β (Aβ) generation and represents a long-standing prime therapeutic target for the treatment of Alzheimer's disease (AD). However, BACE1 inhibitors tested to date in clinical trials have yielded no beneficial outcomes. In fact, prior BACE1 inhibitor trials targeted at ~ 50-90% Aβ reductions in symptomatic or prodromal AD stages have ended in the discontinuation due to futility and/or side effects, including cognitive worsening rather than expected improvement at the highest dose.
View Article and Find Full Text PDFEffects of cabergoline and dimethylcabergoline on the sexual behavior of male rats.
Psychopharmacology (Berl)
April 2024
Department of Psychiatry, University of Minnesota, Minneapolis, MN, 55454, USA.
Rationale: Cabergoline (CAB) is an ergot derivative typically prescribed for the treatment of hyperprolactinemia. It suppresses the release of prolactin through agonist actions on dopamine (DA) D2 receptors; however, it possesses binding affinity for other DA and 5-HT receptors. Side effects that exacerbate valvular heart disease can occur with high doses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!